Clinical Trial Update: GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera® [Phase 3]

View source ↗

Summary

Phase 3 trial update for GP2013 in active rheumatoid arthritis patients previously treated with Rituxan/MabThera; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• GP2013 (rituximab biosimilar)

Snippet

Sponsor: Sandoz | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2017-12-28